The true end customers for Subsys were not the doctors, nor even the patients, but the insurance companies that ultimately needed to foot the bill. Almost all health insurers required prior authorization before they would pay for Subsys. It was a costly and potent drug. A doctor’s prescription wasn’t enough. Insurers wanted to know that a TIRF product was truly necessary and that the cheaper generic Actiq wouldn’t suffice.
